Scholars Central

Conference abstractPublished 11 Aug 2016

Novel treatment options against minimal residual disease in children using a preclinical model of acute leukemia

Authors: Irmela Jeremias

Ludwig Maximilian University of Munich, Germany

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

While first line poly-chemotherapy substantially reduces tumor burden in most children with acute leukemia, a subgroup of children retain residual tumor cells in a disease stage called minimal residual disease (MRD). Despite low tumor burden, MRD represents a major threat as it consists of treatment resistant cells which might induce disease relapse with inferior prognosis. Novel treatment options are urgently required to treat children with acute leukemia at MRD. We aimed at the preclinical testing novel treatment options for MRD. Towards this aim, we established the individualized mouse model of acute leukemias and transplanted primary tumor cells from children with either Acute Lymphoblastic Leukemia (ALL) or Acute Myloid Leukemia (AML) into severely immunocompromised mice and generated patient-derived xenograft cells thereof. Using lenti-viral transduction, we molecularly marked patient-derived xenograft cells with luciferase allowing highly sensitive and reliable bioluminescence in vivo imaging in single mice over time. Imaging allowed establishing a mouse model of MRD using conventional poly-chemotherapy consisting of an anthracycline combined with Cytarabine in AML and a 3 drug poly-chemotherapy for ALL. Using enrichment strategies based on the expression of additional trans-genes, we re-isolated MRD cells from mice and performed single cell RNA sequencing to characterize the cells. We performed second line treatment starting at the disease stage of MRD. Our model allows characterizing MRD cells in more detail and testing novel treatment options to remove MRD cells in order to prevent disease relapse and to improve the prognosis of children with acute leukemias.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Pediatrics & Therapeutics.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalPediatrics & Therapeutics
  • SubjectPaediatrics & Neonatology
  • BylineArticles whose byline prints “Irmela Jeremias”